Analysed SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) News Sources
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
11-06-2026
yahoo.com
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
11-06-2026
yahoo.com
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed
13-06-2026
yahoo.com
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
30-06-2026
yahoo.com
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01-07-2026
yahoo.com
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
14-07-2026
yahoo.com
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
14-07-2026
yahoo.com
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
14-07-2026
marketbeat.com
What is the current price of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The current price of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is $22.8.
SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) absolute price change since previous trading day?
The absolute price change of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) since the previous trading day is $0.09.
SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) percentage price change since previous trading day?
The percentage price change of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) since the previous trading day is 0.3963%.
What is the most recent average sentiment score for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The most recent average sentiment score for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The most recent sentiment for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is .
SEC-8K** Filing Available For SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.